Animal models to study plaque vulnerability

Current Pharmaceutical Design

Volumn 13, Issue 10, 2007, Pages 1013-1020

  Schapira, K ^a   Heeneman, S ^a   Daemen, M J A P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Intravascular ultrasound; Matrix metalloproteinases; Phagocytes; Smooth muscle cell

Indexed keywords

ANGIOTENSIN II; COLLAGEN; VASCULOTROPIN;

ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CORONARY ARTERY DISEASE; HISTOPATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SHEAR STRESS; THROMBOGENESIS;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; RUPTURE, SPONTANEOUS; THROMBOSIS;

EID: 34247873068     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780487575     Document Type: Review

References (89)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
2. Shah PK. Insights into the molecular mechanisms of plaque rupture and thrombosis. Indian Heart J 2005; 57: 21-30.
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-72.
4. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and hiEh-risk plaque: Part I: evolving concepts. J Am Coll Cardiol 2005; 46: 937-54.
5. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
6. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-63.
7. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-43.
8. Davies MJ. Anatomic features in victims of sudden coronary death. Coronary artery pathology. Circulation 1992; 85: I19-24.
9. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20.
10. Kereiakes DJ. The Emperor's clothes: In search of the vulnerable plaque. Circulation 2003; 107: 2076-77.
11. Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation 2003; 107: 2072-75.
12. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003; 107: 2068-71.
13. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 2004; 25: 1077-82.
14. Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Jarvik GP, et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: A high-resolution magnetic resonance imaging study. Circulation 2005; 111: 2768-75.
15. Rudd JH, Davies JR, Weissberg PL. Imaging of atherosclerosis - can we predict plaque rupture? Trends Cardiovasc Med 2005; 15: 17-24.
16. Rioufol G, Gilard M, Finet G, Ginon I, Boschat J, Andre-Fouet X. Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: Long-term follow-up with intravascular ultrasound. Circulation 2004; 110: 2875-80.
17. Bauriedel G, Hutter R, Welsch U, Bach R, Sievert H, Luderitz B. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc Res 1999; 41: 480-8.
18. Bennett MR. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 1999; 41: 361-8.
19. Boyle JJ, Bowyer DE, Weissberg PL, Bennett MR. Human bloodderived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol 2001; 21: 1402-7.
20. Bennett MR, Macdonald K, Chan SW, Boyle JJ, Weissberg PL. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res 1998; 82: 704-12.
21. Leskinen MJ, Kovanen PT, Lindstedt KA. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells--a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol 2003; 66: 1493-8.
22. Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, et al. The dynamic extracellular matrix: Intervention strategies during heart failure and atherosclerosis. J Pathol 2003; 200: 516-25
23. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
24. Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006; 113: 98-107.
25. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-83.
26. Bengtsson E, To F, Hakansson K, Grubb A, Branen L, Nilsson J, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 2151-6.
27. Sukhova GK, Wang B, Libby P, Pan JH, Zhang Y, Grubb A, et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 2005; 96: 368-75.
28. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004; 6: 112-20.
29. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92: 402-6.
30. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
31. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
32. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005; 25: 2255-64.
33. Cheng C, de Crom R, van Haperen R, Helderman F, Gourabi BM, van Damme LC, et al. The role of shear stress in atherosclerosis: Action through gene expression and inflammation? Cell Biochem Biophys 2004; 41: 279-94.
34. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282: 2035-42.
35. Feldman CL, Stone PH. Intravascular hemodynamic factors responsible for progression of coronary atherosclerosis and development of vulnerable plaque. Curr Opin Cardiol 2000; 15: 430-40.
36. Slager CJ, Wentzel JJ, Gijsen FJ, Thury A, van der Wal AC, Schaar JA, et al. The role of shear stress in the destabilization of vulnerable plaques and related therapeutic implications. Nat Clin Pract Cardiovasc Med 2005; 2: 456-64.
37. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25.
38. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-61.
39. Jeziorska M, Woolley DE. Neovascularization in early atherosclerotic lesions of human carotid arteries: Its potential contribution to plaque development. Hum Pathol 1999; 30: 919-25.
40. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability. Circulation 2004; 110: 2032-8.
41. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation 2005; 112: 1813-24.
42. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, et al. Healed plaque ruptures and sudden coronary death: Evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934-40.
43. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: Role of healed plaque disruption. Heart 1999; 82: 265-8.
44. Rittersma SZ, van der Wal AC, Koch KT, Piek JJ, Henriques JP, Mulder KJ, et al. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: A pathological thrombectomy study in primary percutaneous coronary intervention. Circulation 2005; 111: 1160-5.
45. Abela GS, Picon PD, Friedl SE, Gebara OC, Miyamoto A, Federman M, et al. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 1995; 91: 776-84.
46. Nakamura M, Abe S, Kinukawa N. Aortic medial necrosis with or without thrombosis in rabbits treated with Russell's viper venom and angiotensin II. Atherosclerosis 1997; 128: 149-56.
47. Reddick RL, Zhang SH, Maeda N. Aortic atherosclerotic plaque injury in apolipoprotein E deficient mice. Atherosclerosis 1998; 140: 297-305
48. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 1831-4.
49. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, et al. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirusmediated transfer of p53. Circulation 2002; 105: 2064-70.
50. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 2001; 195: 257-63.
51. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol 2000; 20: 2587-92.
52. Herrera VL, Makrides SC, Xie HX, Adari H, Krauss RM, Ryan US, et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 1999; 5: 1383-9.
53. Williams H, Johnson JL, Carson KG, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2002; 22: 788-92.
54. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis 2001; 154: 399-406
55. Rekhter M. Vulnerable atherosclerotic plaque: Emerging challenge for animal models. Curr Opin Cardiol 2002; 17: 626-32.
56. Rekhter MD. How to evaluate plaque vulnerability in animal models of atherosclerosis? Cardiovasc Res 2002; 54: 36-41.
57. Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, et al. Rupture of the atherosclerotic plaque: Does a good animal model exist? Arterioscler Thromb Vasc Biol 2003; 23: 535-42.
58. Lowe HC, Jang IK, Khachigian LM. Animal models of vulnerable plaque. Clinical context and current status. Thromb Haemost 2003; 90: 774-80.
59. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: Model characterization and effects of pravastatin treatment. Circulation 2005; 111: 1422-30.
60. Shimshi M, Abe E, Fisher EA, Zaidi M, Fallon JT. Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun 2005; 328: 790-3.
61. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharmacol 2000; 35: 287-96.
62. Mazzolai L, Duchosal MA, Korber M, Bouzourene K, Aubert JF, Hao H, et al. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension 2004; 44: 277-82.
63. Babamusta F, Rateri DL, Moorleghen JJ, Howatt DA, Li XA, Daugherty A. Angiotensin II infusion induces site-specific intralaminar hemorrhage in macrophage colony-stimulating factordeficient mice. Atherosclerosis 2006; 186(2): 282-90.
64. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-12.
65. Daugherty A, Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci 1999; 892: 108-18.
66. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001; 134: 865-70.
67. de Nooijer R, von der Thusen JH, Verkleij CJ, Kuiper J, Jukema JW, van der Wall EE, et al. Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 2313-9.
68. Zadelaar AS, Thusen JH, LS MB, Hoeben RC, Kockx MM, Versnel MA, et al. Increased vulnerability of pre-existing atherosclerosis in ApoE-deficient mice following adenovirus-mediated Fas ligand gene transfer. Atherosclerosis 2005; 183: 244-50.
69. Stewart FA, Heeneman S, Te Poele J, Kruse J, Russell NS, Gijbels M, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 2006; 168: 649-58.
70. Pakala R, Leborgne L, Cheneau E, Chan RC, Yazdi H, Fournadjiev J, et al. Radiation-induced atherosclerotic plaque progression in a hypercholesterolemic rabbit: A prospective vulnerable plaque model? Cardiovasc Radiat Med 2003; 4: 146-51.
71. Russell JC, Graham SE, Richardson M. Cardiovascular disease in the JCR: LA-cp rat. Mol Cell Biochem 1998; 188: 113-26.
72. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002; 90: 270-6.
73. Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, Weisgraber KH, et al. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation 2005; 111: 3457-64.
74. Yanni AE. The laboratory rabbit: An animal model of atherosclerosis research. Lab Anim 2004; 38: 246-56.
75. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-517.
76. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoEdeficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-40.
77. Smith JD, Breslow JL. The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med 1997; 242: 99-109.
78. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 1998; 39: 8-33.
79. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-82.
80. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein Edeficient mice. Circulation 1999; 99: 1726-32.
81. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003; 100: 4736-41.
82. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-9.
83. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-40.
84. Leppanen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoproteinreceptor/apolipoprotein B48-deficient mice. Circulation 2005; 112: 1347-52.
85. Saito H, Dhanasekaran P, Baldwin F, Weisgraber KH, Phillips MC, Lund-Katz S. Effects of polymorphism on the lipid interaction of human apolipoprotein E. J Biol Chem 2003; 278: 40723-9.
86. Faber BC, Cleutjens KB, Niessen RL, Aarts PL, Boon W, Greenberg AS, et al. Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res 2001; 89: 547-54.
87. Cherubini A, Vigna GB, Zuliani G, Ruggiero C, Senin U, Fellin R. Role of antioxidants in atherosclerosis: Epidemiological and clinical update. Curr Pharm Des 2005; 11(16): 2017-32.
88. Diener HC. Primary and secondary stroke prevention with antiplatelet drugs. Curr Pharm Des 2006; 12(10): 1293-7.
89. Ishisaki A, Matsuno H. Novel ideas of gene therapy for atherosclerosis: modulation of cellular signal transduction of TGF-beta family. Curr Pharm Des 2006; 12(7): 877-86.